2 Thermo Fisher Way
172 articles with ViewRay Incorporated
ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million
ViewRay, Inc. announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay
ViewRay, Inc. announced that the Company will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference in New York, New York. Scott Drake, President and CEO, will give a presentation at 1:30p.m. Eastern Time on Wednesday, December 4, 2019.
ViewRay, Inc. announced financial results for the third quarter ended September 30, 2019..
Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy
ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019
Joint Cancer Program in Boston First in New England to Offer MRI-Guided Radiation Therapy
VRAY NOTICE: ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against ViewRay, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the "Class Period")
ViewRay, Inc. (NASDAQ: VRAY) announced today that Penn State Health has entered into a master agreement for the purchase of up to four MRIdian systems, placing an order for its first system today
Stanford Health Care to Acquire a ViewRay MRIdian System
Leading Radiation Oncology Meeting to Feature Unique Capabilities and Compelling Patient Outcomes with ViewRay's MRIdian
Clinicians from 17 Hospitals Worldwide to Present Clinical Experience with MRIdian MRI-Guided Radiation Therapy at ASTRO
ViewRay, Inc. announced that the Company will host a physician-led informational discussion for investors and analysts during the 2019 American Society of Radiation Oncology Annual Meeting in Chicago.
ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer.
ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY.
ViewRay, Inc. announced financial results for the second quarter ended June 30, 2019.
ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019
ViewRay, Inc. announced details relating to the release of its second quarter 2019 financial results.
ViewRay, Inc. announced the appointment of Dr. Gail Wilensky to its Board of Directors.
Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide